Pseudomonas Aeruginosa Infection Treatment Market Report 2026

The pseudomonas aeruginosa infection treatment market size has grown strongly in recent years. It will grow from $2.65 billion in 2025 to $2.86 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing prevalence of hospital-acquired infections, limited antibiotic pipeline, rising awareness of pseudomonas infections, growth of hospital infrastructure, dependence on intravenous therapies.

The pseudomonas aeruginosa infection treatment market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to advancements in combination therapy, development of novel antipseudomonal agents, expansion of online pharmacy distribution, rising adoption of personalized medicine, integration of telehealth and remote monitoring. Major trends in the forecast period include rising antimicrobial resistance awareness, growth in hospital-acquired infection management, increased use of combination therapy for p. aeruginosa, expansion of intravenous drug delivery systems, adoption of telemedicine for infection monitoring.

The increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infections, and bloodstream infections is expected to drive the growth of the Pseudomonas aeruginosa infection treatment market. Co-morbidities refer to the presence of one or more additional medical conditions alongside a primary condition, often chronic in nature, which can impact either physical or mental health. For example, in September 2023, PubMed published a study showing that 65.5% of people with cystic fibrosis (pwCF) had experienced at least one bacterial or fungal infection, and 27.9% had experienced at least one chronic condition. The study also highlighted the increasing risk of infections like Pseudomonas aeruginosa, with associated health complications. As these comorbidities become more prevalent, the demand for effective treatments for Pseudomonas aeruginosa infections is expected to rise.

To address this growing need, major companies in the Pseudomonas aeruginosa infection treatment market are forming strategic partnerships to improve antibiotic accessibility globally. For instance, in June 2023, Shionogi & Co. Ltd. (Japan), the Global Antibiotic Research and Development Partnership (GARDP, Switzerland), and the Clinton Health Access Initiative (CHAI, U.S.) joined forces to ensure the availability of cefiderocol, a new antibiotic designed to treat severe Gram-negative bacterial infections that may resist alternative antibiotics. Cefiderocol, which targets several WHO-prioritized Gram-negative pathogens, was recently added to the WHO Model List of Essential Medicines.

In March 2024, BiomX Ltd., an Israel-based company, acquired Adaptive Phage Therapeutics for an undisclosed amount, aiming to lead the phage therapy market. The acquisition will focus on developing precision bacteriophage therapies targeting chronic infections, especially those seen in cystic fibrosis patients and diabetic foot osteomyelitis.

Major companies operating in the pseudomonas aeruginosa infection treatment market are AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co Inc., Pfizer Inc., Lupin Limited, AstraZeneca plc, Novartis Pharmaceuticals Corporation, Bayer AG, Johnson & Johnson, Neopharma LLC, Sanofi SA, GlaxoSmithKline plc, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy's Laboratories Ltd., Cipla Inc., Hikma Pharmaceuticals plc, Zydus Cadila Healthcare Limited, Wockhardt Ltd., Mayne Pharma Group Limited, Glenmark Pharmaceuticals Ltd., Perrigo Company plc, Amneal Pharmaceuticals LLC, Apotex Inc., Cadila Healthcare Ltd.

Europe was the largest region in the pseudomonas aeruginosa infection treatment market in 2025. North America is expected to be the fastest-growing region in the pseudomonas aeruginosa infection treatment market report during the forecast period. The regions covered in the pseudomonas aeruginosa infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pseudomonas aeruginosa infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pseudomonas aeruginosa infection treatment market by raising the cost of imported antibiotics, medical equipment, and intravenous delivery devices. These impacts are most prominent in regions such as Europe and North America where imports form a significant portion of supply. Hospital pharmacies and intravenous drug segments face the highest cost pressures, potentially slowing procurement and adoption. However, tariffs have also encouraged local manufacturing and innovation, creating opportunities for domestic suppliers to expand their presence and optimize cost-effective treatments.

The pseudomonas aeruginosa infection treatment market research report is one of a series of new reports that provides pseudomonas aeruginosa infection treatment market statistics, including pseudomonas aeruginosa infection treatment industry global market size, regional shares, competitors with a pseudomonas aeruginosa infection treatment market share, detailed pseudomonas aeruginosa infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pseudomonas aeruginosa infection treatment industry. This pseudomonas aeruginosa infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pseudomonas aeruginosa is a gram-negative, aerobic rod-shaped bacterium from the pseudomonad family, commonly found in soil and water. It holds clinical significance in diagnostic labs and can be transmitted through contaminated breathing equipment, disinfectants, sinks, or through patient-to-patient transfer.

There are two primary approaches to treating Pseudomonas aeruginosa infections: monotherapy and combination therapy. Monotherapy involves using a single treatment method, such as radiation therapy or surgery, to address a specific disease or condition. Treatment for Pseudomonas aeruginosa infections often involves various drug classes, including aminoglycosides, cephalosporins, carbapenems, monobactams, and others. These treatments can be administered via nasal, oral, or intravenous routes. Medications are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The pseudomonas aeruginosa market consists of sales of biofilm formation, motility (pili, flagella), pigment (pyocyanin), cytotoxins, phospholipases, elastases, and proteases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.